ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
about
Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancerPharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studiesAntivascular therapy for epithelial ovarian cancer.Endothelin B receptor, a new target in cancer immune therapy.Anti-endothelin drugs in solid tumors.Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer.Endothelin-1/endothelin A receptor-mediated biased signaling is a new player in modulating human ovarian cancer cell tumorigenesis.Role of the endothelin axis and its antagonists in the treatment of cancerEndothelin.Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist.Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence.Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in MiceTreatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel.Targeting the endothelin system: novel therapeutic options in gynecological, urological and breast cancers.ETA selective receptor antagonism prevents ventricular remodeling in volume-overloaded rats.Rendomab B4, a monoclonal antibody that discriminates the human endothelin B receptor of melanoma cells and inhibits their migration.The Role of Endocrine G Protein-Coupled Receptors in Ovarian Cancer Progression.The importance of endothelin axis in initiation, progression, and therapy of ovarian cancer.Immunomodulation using agonists and antagonists: potential clinical applications.Diagnostic and prognostic role of matrix metalloproteases in cancer.The EMT spectrum and therapeutic opportunities.Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.
P2860
Q21195213-F5E127D2-E241-4F64-B6BB-27FB2223090EQ21254636-EC7F118D-59C2-4526-99A3-C7BEFA587FDDQ33583598-5A65FB43-D2A0-4897-8BFB-0E9E318A76C5Q33960710-94EAF647-C006-4F22-B1D6-FC7990459B17Q34021011-7A369B12-8D9A-4FD7-8CF7-1ECDDE2CDEAEQ34161050-388DB2A4-017D-4614-A0F7-F1AA73463DEDQ34551567-6AE62685-F600-470C-8844-57187BF87449Q34624192-2F434E65-F7E1-4D4B-9245-0392879B98C8Q34919570-1F052114-7171-47CB-A4AC-F3296B391BFBQ35120667-62AE8D12-EC4E-4009-9640-538E25B1A7C8Q35762215-003EED1B-82A4-4C10-98D8-DCDC451D8B4DQ36163574-6A6C14EF-A5E7-483B-8312-622691F36E7EQ36657607-A089F7E7-1A6D-424B-8D6E-38D7607F371FQ36705944-B41918F2-8A79-4F05-95A6-5956083EB7DAQ37256842-9FBAB07C-A7D7-4E12-A06A-5DCA0F7114CCQ37264443-722F52DD-2264-498E-B5D5-5FCC5514C685Q37327310-A5186769-3780-4173-8B75-61B101C424E3Q37740526-8E19232A-5ADA-466A-B76F-E60A82E956E6Q37764250-4BC5E77B-1B50-4C0D-9AC4-63FF27DF0DCFQ37965728-96E483B5-7288-44E4-AF79-FB4A5A33B704Q38089795-76276303-AB60-48D2-AF92-112FCF54067BQ39329818-7E32BD57-696A-40E1-BF3D-C543BB995579Q39680529-0E41E9EE-0653-4C30-9996-FD153FA20F5FQ45883136-F6A46044-FD76-4457-9E3B-450DB88087BC
P2860
ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
ZD4054, a specific antagonist ...... arcinoma in vitro and in vivo.
@en
type
label
ZD4054, a specific antagonist ...... arcinoma in vitro and in vivo.
@en
prefLabel
ZD4054, a specific antagonist ...... arcinoma in vitro and in vivo.
@en
P2093
P1476
ZD4054, a specific antagonist ...... arcinoma in vitro and in vivo.
@en
P2093
Anna Bagnato
Francesca Spinella
Laura Rosanò
Maria Rita Nicotra
Pier Giorgio Natali
Valeriana Di Castro
P304
P356
10.1158/1535-7163.MCT-07-0151
P577
2007-07-01T00:00:00Z